Radiopharm Theranostics Limited ADR RADX

$1.01 +0.06 (6.32%)

Valuation

Market cap: 14,918,000
Revenue TTM: $1,880,000
Net income TTM: $-38,650,000
PE ratio: 0.00
Forward PE: —
Profit margin: -2,055.85%
Debt to equity: 0.00

Trading

Volume: 32,400
Avg volume: 59,774
Day's range: $1.00 – $1.07
Shares out: 15,703,000
Stochastic %K: 26%
Beta: 1.78
Analysts: Strong Sell
Price target: $17.08

Price

Company profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Website: https://www.radiopharmtheranostics.com
Address: 62 Lygon Street, Level 3, Carlton, Australia

Latest news

No headlines yet.

Stocktwits

__LucidDreamer__ Oct 23, 5:32 PM

$CATX Target: $0.70 Why? Because all speculative shitty biotech stocks seem destined for that level. Good news: if it hits $.070 then you sell at $2 for a massive win when the heavily share-comped execs are “aligned with shareholders”. $RADX $ESPR

0 replies

LewisIntegrated Oct 23, 5:15 PM

If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $RADX $APLM

0 replies

twitofstock Oct 23, 3:19 PM

$RADX what a strange color, ive never seen it before !

1 replies

Lalalilala Oct 23, 1:09 PM

$RADX Halted $CATX

0 replies

Lalalilala Oct 22, 7:50 PM

$RADX We're going to close below $1 for the 5th consecutive day....

0 replies

Ontherag Oct 22, 7:43 PM

$RADX make sure you sell on the next pop. This company was designed for selling on catalysts.

1 replies

Manpreet00 Oct 22, 7:39 PM

$RADX even with the reverse split and a further CR, the stock has the potential to eventually trade around $7-$8. Still pretty good. Throw in the anticipated RAD101 partnership and things become even more interesting. Everyone is angry they won’t get to sell at $20/share like they wanted. They have destroyed the potential for it go above $10 but we can still break even and make money. Might just take few more months

1 replies

Lalalilala Oct 22, 6:31 PM

$RADX @VetteAlpine , I partially agree, but a licensing agreement isn't "worthless": A licensing agreement for RAD101 is not a minor event. In the radiopharmaceutical industry, when a giant like Lantheus, Curium, or Siemens PETNET licenses a Phase 3 product, the agreement very often comes with an immediate upfront cash payment of several million or tens of millions of dollars. Furthermore, by transferring the cost of a 320-patient trial to a partner, Radiopharm eliminates the risk of having to raise a large, dilutive amount of capital. For a biotech company whose market capitalization has fallen below $15 million, securing such a partnership provides a crucial lifeline to secure its cash flow. We'll know for sure soon...

0 replies